CN111393493B - Synthetic method of tildipirosin - Google Patents

Synthetic method of tildipirosin Download PDF

Info

Publication number
CN111393493B
CN111393493B CN202010224650.XA CN202010224650A CN111393493B CN 111393493 B CN111393493 B CN 111393493B CN 202010224650 A CN202010224650 A CN 202010224650A CN 111393493 B CN111393493 B CN 111393493B
Authority
CN
China
Prior art keywords
tylonolide
mycaminosyl
tildipirosin
piperidyl
iodo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010224650.XA
Other languages
Chinese (zh)
Other versions
CN111393493A (en
Inventor
李有志
马居良
殷习栋
杨统鹏
郑真真
宋晶晶
赵延东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Jiulong Jiulong Pharmaceutical Co ltd
Shandong Jiulong Hisince Pharmaceutical Co ltd
Original Assignee
Jinan Jiulong Jiulong Pharmaceutical Co ltd
Shandong Jiulong Hisince Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Jiulong Jiulong Pharmaceutical Co ltd, Shandong Jiulong Hisince Pharmaceutical Co ltd filed Critical Jinan Jiulong Jiulong Pharmaceutical Co ltd
Priority to CN202010224650.XA priority Critical patent/CN111393493B/en
Publication of CN111393493A publication Critical patent/CN111393493A/en
Application granted granted Critical
Publication of CN111393493B publication Critical patent/CN111393493B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The invention belongs to the technical field of chemical synthesis, and particularly relates to a synthetic method of a tildipirosin intermediate. The method comprises the following steps: (1) Preparing 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide; and (2) preparing the tildipirosin. The method has the advantages of simple treatment process, small amount of waste liquid, low environmental protection treatment cost, high product yield and high purity of the obtained product.

Description

Synthetic method of tildipirosin
Technical Field
The invention belongs to the technical field of chemical synthesis, and particularly relates to a tildipirosin intermediate and a synthetic method of tildipirosin.
Background
Tildipirosin has a chemical formula of C 41 H 71 N 3 O 8 The chemical name of the derivative is 20, 23-dipiperidinyl-5-O-mycaminosyl-tylonolide, and the structural formula is as follows:
Figure BDA0002427245270000011
tylosin (tildipiriosin), a new semi-synthetic macrolide antibiotic developed by International corporation of integwort (International BV) in the netherlands, which is a special macrolide for animals, is a derivative of tylosin. Sterile injection with tildipirosin as main effective componentAgent (trade name:
Figure BDA0002427245270000012
) Approved for marketing in the European union countries after approval by the European pharmaceutical administration (EMA) in 2011. Can be used for preventing and treating respiratory system infectious diseases of pig and cattle caused by sensitive bacteria such as Haemophilus parasuis, actinobacillus pleuropneumoniae, pasteurella multocida and Mannheim hemolyticus. After single intramuscular injection or subcutaneous injection administration, the tildipirosin has the advantages of quick absorption, short peak reaching time, high concentration in lung tissues, high bioavailability, slow elimination, lasting drug effect, high safety, capability of providing whole-course treatment after single administration and the like, and has wide application prospect.
The antibacterial action of the tylosin is similar to that of tylosin, has strong antibacterial action on gram-positive bacteria and partial gram-negative bacteria, is particularly sensitive to pathogenic bacteria causing respiratory system diseases of pigs and cattle, such as pasteurella multocida, actinobacillus pleuropneumoniae, bordetella bronchiseptica, haemophilus parasuis, haemolytic Mannheim, histophilus somni, mycoplasma, spirochete, brucella and the like, has the same antibacterial action mechanism as macrolide medicaments such as tylosin and the like, can be combined with 50s subunits of nucleoproteins of sensitive bacteria to inhibit and prevent the synthesis and extension of nucleoprotein peptide chains, and further influence the synthesis of bacterial proteins.
The 20-piperidyl-23-iodine-5-O-mycaminosyl-tylonolide is an important intermediate for synthesizing tildipirosin, and the structural formula is as follows:
Figure BDA0002427245270000013
20-piperidinyl-23-iodo-5-O-mycaminosyl-tylonolide is commercially difficult to purchase and is usually synthesized by itself.
At present, the literature reports mainly include the following methods for synthesizing the intermediate of tildipirosin:
in the patent WO2008012343, tylosin is used as a raw material, and a final product is obtained by 5 steps of amination of piperidine on 20 th position, hydrolysis twice, activation on 23 th position and amination. In the method, the hydrogen bromide solution is hydrolyzed at different temperatures twice, the treatment process is complicated, the amount of waste liquid is large, and a large amount of waste liquid containing high-concentration organic solvent is generated after iodine and pyridine are used for substitution, so that the waste liquid treatment cost is greatly increased, and the yield of the method is only 12.2 percent, so that the production cost is high, and the method is not suitable for industrial production. The specific synthetic formula of the route is as follows:
Figure BDA0002427245270000021
patent CN102863487 reports that tylosin tartrate is used as a raw material, intermediate 23-hydroxy-5-O-mycaminosyl-tylonolide is obtained by hydrolysis, iodination is carried out, and then the intermediate and piperidine are aminated to form the final product tylosin. The method has the disadvantages that triphenylphosphine, imidazole, iodine and the like are used, anhydrous conditions are required for reaction, requirements on equipment and production conditions are high, the amount of generated high-concentration waste liquid containing imidazole and triphenylphosphine is large, the environment-friendly treatment cost is increased, the cost is not reduced, and industrial production is realized.
The specific synthetic formula of the route is as follows:
Figure BDA0002427245270000031
U.S. Pat. No. 6,6514946 of Japan society for the research of microbiology, uses 20,30-diiodo-5-O-mycaminose-tylonolide as raw material, reacts with piperidine in acetonitrile, and the product is obtained by column chromatography, the yield is 86.4%. The raw materials are not easy to obtain, column chromatography is utilized, the defects of the column chromatography are complex separation process, long time consumption and large solvent amount, and the method has low efficiency and is not suitable for industrial production in actual production.
Patent CN105254693A discloses a preparation method of 20-piperidyl-23-I-5-O-mycaminosyl-tylonolide, which comprises the following steps: (1) Preparation of 20-piperidinyl-5-O-mycaminosyl-tylonolide: dissolving 18.3g of tylosin, 4.2g of piperidine and 1.4g of formic acid in 50ml of toluene, heating to 75 ℃, reacting for 1 hour, cooling to room temperature, adding 60ml of water, heating to 35 ℃, adjusting pH =2.5 by using 60% sulfuric acid solution, and hydrolyzing for 1 hour. After the reaction, the reaction solution was cooled to room temperature, 40ml of dichloromethane was added, and pH =10 was adjusted with 10N sodium hydroxide solution, the layers were separated, the aqueous phase was washed twice with 10ml of dichloromethane, and the organic phases were combined and dried over anhydrous sodium sulfate for use. (2) Preparation of 20-piperidinyl-23-I-5-O-mycaminosyl-tylonolide: adding 5.2g of hexamethyldisilazane into the dried dichloromethane solution, reacting at 30 ℃ for 2.5 hours (no ammonia gas is released), cooling the reaction solution to room temperature, adding 11.9g of N, N-diethylaniline and 10.0g of iodotrimethylsilane, reacting at 30 ℃ for 2 hours, cooling to room temperature, adding 60ml of water, stirring for 2 hours, demixing, adjusting the pH of the aqueous phase with 10N sodium hydroxide solution =10, filtering, washing, and drying to obtain 14.3g of the product. In the production process of the method, the release of a large amount of ammonia has high requirements on safety protection measures of production environment and professional literacy of workers, and has relatively special requirements on corrosion resistance of equipment, and meanwhile, the use of a large amount of N, N-diethylaniline and trimethyliodosilane causes the COD (chemical oxygen demand) in the production wastewater to be very high, so that the environmental-protection treatment cost is increased.
Patent CN104558076A relates to a preparation method of 20-piperidyl-23-iodo-5-O-mycylamine glycosyl-tylonolide, which specifically comprises the following steps:
Figure BDA0002427245270000041
dichloromethane (120ml, 20V), pyridine (4.8g, 61mmol, 6.0eq), triphenylphosphine (15.7g, 61mmol, 6.0eq) were added into a three-necked flask, the mixture was stirred thoroughly until the system solution became clear, the temperature was maintained at 15 ℃, the iodine simple substance (15.3g, 61mmol, 6.0eq) was added in portions, after the addition, the system was allowed to warm to room temperature naturally, the reaction mixture was stirred for 1 hour, a dichloromethane (60ml, 10V) solution of compound 3 (6.0g, 10.0mmol, 1.0eq) was added dropwise at 15 ℃, after the addition, the temperature was naturally raised to room temperature, the reaction mixture was stirred for 4 hours, and the disappearance of the starting material was detected by HPLC. The reaction was quenched by addition of sodium sulfite solution at 15 ℃, the organic phase was adjusted to PH 1-2 with hydrochloric acid (1N), extracted with dichloromethane (3 × 100 ml), the aqueous phase was adjusted to PH 8-9 with saturated sodium bicarbonate solution and then extracted with dichloromethane (3 × 100 ml), the organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated to give 7.17 g of a yellow solid with 95% purity in 88% yield. According to the method, iodination reaction needs to be carried out on 2 hydroxyl groups in the reaction, the activity of the iodine is high, iodination reaction can be carried out on 4 hydroxyl groups on 20-hydroxyl-23-iodine-5-O-mycaminosyl-tylonolide at a chance, the purity of the product is low, and the post-treatment purification process is complicated.
Disclosure of Invention
In order to solve the technical problems, the invention provides a synthetic method of a tildipirosin intermediate, which has low requirements on equipment and production conditions, is simple to operate, has short reaction time, can repeatedly recycle a catalyst, has high yield, has high product purity, does not have special solvents which are difficult to treat, has little waste liquid and has low waste liquid treatment cost.
The invention is realized by the following technical scheme:
a method for synthesizing a tildipirosin intermediate, wherein the tildipirosin intermediate is 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide, is characterized by comprising the following steps:
the 20-piperidyl-5-O-mycaminosyl-tylonolide and hydroiodic acid are subjected to reflux reaction to obtain the 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide.
The reaction formula is as follows:
Figure BDA0002427245270000051
in the synthesis method of the tildipirosin intermediate, the reaction solvent is acetonitrile.
In the synthesis method of the tildipirosin intermediate, the weight ratio of the 20-piperidyl-5-O-mycaminosyl-tylonolide to the hydroiodic acid is 1:055-0.62.
In the synthesis method of the tildipirosin intermediate, the concentration of hydroiodic acid is 50-60% by mass.
In the above method for synthesizing the tildipirosin intermediate, the concentration of hydroiodic acid is 57% by mass.
In the synthesis method of the tildipirosin intermediate, the reaction time is 4-5h.
In the above method for synthesizing the intermediate of tildipirosin, the reaction further comprises a post-treatment step, wherein the post-treatment step is: after the reaction is finished, concentrating under reduced pressure until no solvent exists basically, adding water, adjusting the pH to 11-12 by using a sodium hydroxide solution, stirring for 15-20min, carrying out suction filtration, and drying to obtain a product 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide.
The detailed steps of the synthesis method of the tildipirosin intermediate are as follows:
adding 20-piperidyl-5-O-mycaminosyl-tylonolide into acetonitrile, stirring, adding hydriodic acid (57%), refluxing for 4.5h, concentrating under reduced pressure until no solvent exists basically, adding water, adjusting pH to 11-12 with sodium hydroxide solution, stirring for 15-20min, performing suction filtration, and drying to obtain 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide.
The method for synthesizing the tildipirosin, which comprises the method for synthesizing the intermediate of tildipirosin, comprises the following steps:
(1) Preparation of 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide
Adding 20-piperidyl-5-O-mycaminosyl-tylonolide into acetonitrile, stirring, adding hydroiodic acid (57%), refluxing for 4.5h, concentrating under reduced pressure until no solvent exists basically, adding water, adjusting the pH to 11-12 with a sodium hydroxide solution, stirring for 15-20min, carrying out suction filtration, and drying to obtain 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide;
(2) Preparation of tildipirosin
Dissolving 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide in butyl acetate, adding piperidine and potassium carbonate, heating and refluxing for 3 hours, filtering, adding purified water into the filtrate, adjusting the pH value to 4.0 by using hydrochloric acid, separating a water phase, washing the water phase by using dichloromethane, adjusting the pH value to 10 by using 4mol/L sodium hydroxide, stirring for 1 hour, filtering, and drying a filter cake to obtain the tildipirosin.
Compared with the prior art, the invention has the following beneficial effects:
(1) The synthesis method of the tildipirosin intermediate 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide adopts hydroiodic acid for one-time hydrolysis preparation, and has the advantages of simple treatment process, small amount of generated waste liquid, environmental protection and low treatment cost.
(2) The synthesis method of the tildipirosin intermediate 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide does not involve raw materials such as triphenylphosphine, iodine, imidazole and pyridine which have special odor or generate odor after reaction, is more green in production process, does not need special harsh conditions for reaction, has lower requirements on equipment and production conditions, avoids generating a large amount of high-concentration waste liquid, is low in environmental protection treatment cost, and is beneficial to industrial production.
(3) The synthesis method of the tildipirosin intermediate 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide has the advantages of easily obtained raw materials, no need of column chromatography, simple separation process, short time consumption, small solvent amount, high production efficiency and suitability for industrial production.
(4) The synthesis method of the tildipirosin intermediate 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide has the advantages of high product yield and high purity of the obtained product.
Detailed Description
The present invention will be further described with reference to specific examples so that those skilled in the art may better understand the present invention, but the present invention is not limited thereto.
Example 1 Synthesis of 20-piperidinyl-23-iodo-5-O-mycaminosyl-tylonolide
Adding 71.5kg of 20-piperidyl-5-O-mycylamine glycosyl-tylonolide (1) and 160kg of acetonitrile into a 500L reaction kettle, stirring, adding 44.1kg of hydroiodic acid (57%), performing reflux reaction for 4.5 hours, concentrating under reduced pressure until the mixture is basically free of solvent, adding water, adjusting the pH value to 11 by using a sodium hydroxide solution, stirring for 20min, performing suction filtration and drying to obtain 63.0kg of a product 20-piperidyl-23-iodo-5-O-mycylamine glycosyl-tylonolide (2), wherein the yield is 95.4%, and the purity is 98.1%.
EXAMPLE 2 Synthesis of 20-piperidinyl-23-iodo-5-O-mycaminosyl-tylonolide
Adding 71.5kg of 20-piperidyl-5-O-mycylamine glycosyl-tylonolide (1) and 160kg of acetonitrile into a 500L reaction kettle, stirring, adding 44.1kg of hydroiodic acid (57%), performing reflux reaction for 4.5 hours, concentrating under reduced pressure until the mixture is basically free of solvent, adding water, adjusting the pH value to 12 by using a sodium hydroxide solution, stirring for 20min, performing suction filtration and drying to obtain 63.2kg of a product 20-piperidyl-23-iodo-5-O-mycylamine glycosyl-tylonolide (2), wherein the yield is 95.8% and the purity is 98.3%.
EXAMPLE 3 Synthesis of 20-piperidinyl-23-iodo-5-O-mycaminosyl-tylonolide
Adding 71.5kg of 20-piperidyl-5-O-mycaminosyl-tylonolide (1) and 160kg of acetonitrile into a 500L reaction kettle, stirring, adding 39.5kg of hydroiodic acid (57%), performing reflux reaction for 4.5h (the reaction kettle is connected with a tail gas absorption tank), concentrating under reduced pressure until no solvent exists basically, adding water, adjusting the pH to 12 by using a sodium hydroxide solution, stirring for 20min, performing suction filtration and drying to obtain 62.9kg of a product 20-piperidyl-23-iodine-5-O-mycaminosyl-tylonolide (2), wherein the yield is 95.3%, and the purity is 98.5%.
EXAMPLE 4 Synthesis of 20-piperidinyl-23-iodo-5-O-mycaminosyl-tylonolide
Adding 71.5kg of 20-piperidyl-5-O-mycylamine glycosyl-tylonolide (1) and 160kg of acetonitrile into a 500L reaction kettle, stirring, adding 44.5kg of hydroiodic acid (57%), performing reflux reaction for 4.5 hours, concentrating under reduced pressure until the mixture is basically free of solvent, adding water, adjusting the pH value to 12 by using a sodium hydroxide solution, stirring for 20min, performing suction filtration and drying to obtain 63.2kg of a product 20-piperidyl-23-iodo-5-O-mycylamine glycosyl-tylonolide (2), wherein the yield is 95.7%, and the purity is 98.4%.
Example 5
(1) Synthesis of 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide
Adding 71.5kg of 20-piperidyl-5-O-mycaminosyl-tylonolide (1) and 160kg of acetonitrile into a 500L reaction kettle, stirring, adding 41.7kg of hydroiodic acid (57%), performing reflux reaction for 4.5h (a tail gas absorption tank is connected to the reaction kettle), concentrating under reduced pressure until no solvent exists basically, adding water, adjusting the pH to 12 by using a sodium hydroxide solution, stirring for 20min, performing suction filtration and drying to obtain 63.2kg of a product 20-piperidyl-23-iodine-5-O-mycaminosyl-tylonolide (2), wherein the yield is 95.7%, and the purity is 98.3%.
(2) Preparation of tildipirosin
In a 500L reaction kettle, dissolving 56.6kg of 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide with 200kg of butyl acetate, adding 27kg of piperidine and 55kg of potassium carbonate, heating and refluxing for 3h, filtering, adding 200kg of purified water into the filtrate, adjusting the pH to 4.0 with hydrochloric acid, separating out an aqueous phase, washing the aqueous phase with 30kg of dichloromethane, adjusting the pH to 10 with 4mol/L of sodium hydroxide, stirring for 1h, filtering, drying a filter cake to obtain 49.2kg of tedizonew, wherein the yield is 91.9%, and the HPLC purity is 98.2%.

Claims (1)

1. A synthetic method of tildipirosin is characterized by comprising the following steps:
(1) Preparation of 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide
Adding 20-piperidyl-5-O-mycaminosyl-tylonolide into acetonitrile, stirring, adding 57% hydriodic acid, refluxing for 4.5h, connecting a reaction kettle to a tail gas absorption tank, concentrating under reduced pressure until no solvent exists basically, adding water, adjusting the pH to 11-12 by using a sodium hydroxide solution, stirring for 15-20min, carrying out suction filtration, and drying to obtain 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide;
(2) Preparation of tildipirosin
Dissolving 20-piperidyl-23-iodo-5-O-mycaminosyl-tylonolide with butyl acetate, then adding piperidine and potassium carbonate, heating and refluxing for 3h, filtering, adding purified water into filtrate, adjusting the pH value to 4.0 with hydrochloric acid, separating out a water phase, washing the water phase with dichloromethane, adjusting the pH value to 10 with 4mol/L sodium hydroxide, stirring for 1h, filtering, and drying a filter cake to obtain the tildipirosin.
CN202010224650.XA 2018-08-22 2018-08-22 Synthetic method of tildipirosin Active CN111393493B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010224650.XA CN111393493B (en) 2018-08-22 2018-08-22 Synthetic method of tildipirosin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810960316.3A CN108822162B (en) 2018-08-22 2018-08-22 Synthetic method of tildipirosin intermediate
CN202010224650.XA CN111393493B (en) 2018-08-22 2018-08-22 Synthetic method of tildipirosin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201810960316.3A Division CN108822162B (en) 2018-08-22 2018-08-22 Synthetic method of tildipirosin intermediate

Publications (2)

Publication Number Publication Date
CN111393493A CN111393493A (en) 2020-07-10
CN111393493B true CN111393493B (en) 2022-12-06

Family

ID=64150434

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810960316.3A Active CN108822162B (en) 2018-08-22 2018-08-22 Synthetic method of tildipirosin intermediate
CN202010224650.XA Active CN111393493B (en) 2018-08-22 2018-08-22 Synthetic method of tildipirosin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810960316.3A Active CN108822162B (en) 2018-08-22 2018-08-22 Synthetic method of tildipirosin intermediate

Country Status (1)

Country Link
CN (2) CN108822162B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115322232A (en) * 2022-08-05 2022-11-11 艾美科健(中国)生物医药有限公司 Method for preparing tylonolide isomer

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101172989A (en) * 2006-11-03 2008-05-07 上海睿智化学研究有限公司 Method for producing 5-O-acetyl-3-deoxidization-1,2-isopropylidene-alpha-D-tetrol xylose and midbody
CN102863487A (en) * 2012-10-08 2013-01-09 齐鲁动物保健品有限公司 Process for preparing 20,23-bi-piperidyl-5-O-carbon mould amine glycosyl-tylosin lactone
CN104497082A (en) * 2015-01-13 2015-04-08 中国兽医药品监察所 Synthetic method for Tildipirosin
CN104558076A (en) * 2015-02-10 2015-04-29 上海皓元化学科技有限公司 Preparation method of tildipirosin and intermediate compounds of tildipirosin
CN105254693A (en) * 2015-11-13 2016-01-20 周金华 Synthetic method for tildipirosin
CN105384788A (en) * 2015-12-14 2016-03-09 天津市中升挑战生物科技有限公司 Tildipirosin preparation method
CN105440093A (en) * 2015-11-17 2016-03-30 宁夏泰瑞制药股份有限公司 Synthetic method of tildipirosin
CN108264529A (en) * 2016-12-30 2018-07-10 湖北回盛生物科技有限公司 A kind of synthetic method of bis- piperidines -5-O- mycamino syl-tylono lides of 20,23-

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101172989A (en) * 2006-11-03 2008-05-07 上海睿智化学研究有限公司 Method for producing 5-O-acetyl-3-deoxidization-1,2-isopropylidene-alpha-D-tetrol xylose and midbody
CN102863487A (en) * 2012-10-08 2013-01-09 齐鲁动物保健品有限公司 Process for preparing 20,23-bi-piperidyl-5-O-carbon mould amine glycosyl-tylosin lactone
CN104497082A (en) * 2015-01-13 2015-04-08 中国兽医药品监察所 Synthetic method for Tildipirosin
CN104558076A (en) * 2015-02-10 2015-04-29 上海皓元化学科技有限公司 Preparation method of tildipirosin and intermediate compounds of tildipirosin
CN105254693A (en) * 2015-11-13 2016-01-20 周金华 Synthetic method for tildipirosin
CN105440093A (en) * 2015-11-17 2016-03-30 宁夏泰瑞制药股份有限公司 Synthetic method of tildipirosin
CN105384788A (en) * 2015-12-14 2016-03-09 天津市中升挑战生物科技有限公司 Tildipirosin preparation method
CN108264529A (en) * 2016-12-30 2018-07-10 湖北回盛生物科技有限公司 A kind of synthetic method of bis- piperidines -5-O- mycamino syl-tylono lides of 20,23-

Also Published As

Publication number Publication date
CN111393493A (en) 2020-07-10
CN108822162A (en) 2018-11-16
CN108822162B (en) 2020-03-17

Similar Documents

Publication Publication Date Title
CN102295672B (en) Synthetic method for tylosin
CN103880903B (en) A kind of preparation method of tylosin class macrolide and derivant thereof
CN1302004C (en) Preparing method for cytarabine
CN111393493B (en) Synthetic method of tildipirosin
CN110128486B (en) Synthesis method of tulathromycin
CN103665084A (en) Method for preparing abiraterone acetate
CN110551123A (en) Preparation method of 5- (tert-butyloxycarbonyl) -2-methyl-4, 5,6, 7-tetrahydro-2H-pyrazolo [4,3-C ] pyridine-7-carboxylic acid
CN113121625B (en) Preparation method of tylosin
CN102464699A (en) Method for preparing carbenoxolone sodium
CN113501771B (en) Preparation method of N- (2-aminoethyl) glycine derivative
CN111892509B (en) Preparation method of minocycline
CN114717280A (en) Synthesis method of monopilavir
CN107200763A (en) A kind of method using chenodeoxycholic acid as Material synthesis lithocholic acid
CN109824687B (en) Novel synthetic method of xylofuranose derivative
CN110066301B (en) Synthesis method of clindamycin phosphate
CN110938036A (en) Preparation method of 4-iodine-1H-imidazole
CN111548356A (en) Process for preparing tert-butyl-1, 8-dioxa-4, 11-diazaspiro [5.6] dodecane-11-carboxylic acid ester
CN108997454B (en) Chemical synthesis method of beta-arbutin
CN114105848B (en) Preparation method of cis-D-hydroxyproline derivative
CN113929587B (en) The method comprises the following steps of14Preparation method of C-marked 2-amino-5-chlorophenol
CN114195684B (en) Synthesis method of amino protecting group N-substituted chiral amino acid
CN110551129B (en) Preparation method of 4, 5-dihydro-1H, 3H-pyrrolo [1,2-A ] [1,4] diazepine-2, 4-dicarboxylic acid-2-tert-butyl ester
CN114920789B (en) Preparation method of tylosin key intermediate
CN112110868A (en) Preparation method of Fmoc-beta-Ala-AA-OH
JP2512050B2 (en) Novel antifungal antibiotic dexylosylvenanomycin B and method for producing the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Li Youzhi

Inventor after: Ma Juliang

Inventor after: Yin Xidong

Inventor after: Yang Tongpeng

Inventor after: Zheng Zhenzhen

Inventor after: Song Jingjing

Inventor after: Zhao Yandong

Inventor before: Ma Juliang

Inventor before: Yin Xidong

Inventor before: Yang Tongpeng

Inventor before: Zheng Zhenzhen

Inventor before: Song Jingjing

Inventor before: Zhao Yandong

CB03 Change of inventor or designer information
TA01 Transfer of patent application right

Effective date of registration: 20221114

Address after: 251100 Huadian entrepreneurship Park, Huadian Township, Qihe County, De Zhou City, Shandong Province

Applicant after: SHANDONG JIULONG HISINCE PHARMACEUTICAL Co.,Ltd.

Applicant after: JINAN JIULONG JIULONG PHARMACEUTICAL CO.,LTD.

Address before: 251110 Shandong Jiulong Hengxin Drug Co.,Ltd., Huadian Xianghuadian Pioneer Park, Qihe County, Dezhou City, Shandong Province

Applicant before: SHANDONG JIULONG HISINCE PHARMACEUTICAL Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant